The 4 most recent market catalysts affecting $ACOG, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 1, 2026
Corporate Catalyst
Neutral
Impact 65
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine
Alpha Cognition released initial 180-day data from its CONVERGE program, which is a real-world evidence study for its drug ZUNVEYL (benzgalantamine) and other acetylcholinesterase …
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21
B. Riley Securities analyst William Woods has initiated coverage on Alpha Cognition (ACOG) with a 'Buy' rating and a $21 price target. This event is significant because new analyst…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 60
HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a 'Buy' rating on Alpha Cognition (ACOG) and raised the price target from $18 to $20. This indicates a strengthened positi…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M Estimate
Alpha Cognition (ACOG) released its Q2 earnings, showing a mixed performance. While the company's loss per share of $(0.40) was slightly worse than the analyst consensus of $(0.39)…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.